The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The outcomes with CAR-T for LBCL in the UK according to ethnicity and socioeconomic deprivation
Andrea Kuhnl, MD, King’s College Hospital, London, United Kingdom, provides insight into the disparities in CAR T-cell therapy access and outcomes in patients with large B-cell lymphoma (LBCL) in the United Kingdom. A study highlighted that patients from highly deprived communities are less likely to receive CAR-T due to access barriers and higher dropout rates, resulting in an inferior overall survival (OS) rate. Dr Kuhnl notes that despite disparities in access, patients from deprived areas who do receive CAR-T treatment do not show differences in efficacy or toxicity outcomes compared to those from less deprived areas. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So we looked at referral patterns and outcomes according to patients’ ethnicity and socio-economic deprivation across three large UK CAR-T centres, Manchester, Birmingham and King’s in London. Our data suggests that those patients from highly deprived communities are less likely to receive CAR-T, firstly because there appeared to be some access barriers...
So we looked at referral patterns and outcomes according to patients’ ethnicity and socio-economic deprivation across three large UK CAR-T centres, Manchester, Birmingham and King’s in London. Our data suggests that those patients from highly deprived communities are less likely to receive CAR-T, firstly because there appeared to be some access barriers. We saw patients from deprived areas being underrepresented in the CAR-T referred population, but also those who were referred to CAR-T centres – those 20% from highly deprived areas had a lower infusion rate or higher dropout rate, which did translate into inferior overall survival in the intention-to-treat population. But those patients who made it to infusion, we didn’t see any difference in efficacy or toxicity outcomes according to ethnicity or deprivation groups.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Kite Gilead, Roche, Abbvie, BMS; Honoraria: Kite Gilead, Astra Zeneca.
